NICE has said MSD’s cancer immunotherapy, Keytruda, should receive interim funding on the NHS in certain patients with untreated lung cancer, in combination with chemotherapy. In first draft guidance, NICE said Keytruda (pembrolizumab) will be rei...
Original Article: Thousands to benefit as NHS funds Keytruda lung cancer combo